157 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF S4: OVERVIEW OF THE EXCLUDED STUDIES BASED ON FULL-TEXT SCREENING, INCLUDING REASON FOR EXCLUSION. Author Year Reference Reason for exclusion Lafon 2018 1 No full-text available Aguilar 2021 2 Highly selected group of patients or data on patients with non-valvular atrial fibrillation cannot be extracted Alcusky 2018 3 Alghadeer 2017 4 Alnsasra 2018 5 Altay 2017 6 Asahina 2020 7 Chaudhry 2021 8 de Almeida 2020 9 Eschler 2021 10 Frol 2020 11 George 2019 12 Gurevitz 2021 13 Haque 2021 14 Inohara 2020 15 Jackevicius 2021 16 Khan 2016 17 Kim 2019 18 Kwon 2016 19 Lafon 2017 20 Mitrovic 2017 21 Nahornyj 2020 22 Paciaroni 2019 23 Rutherford 2021 24 Shinoda 2018 25 Shinohara 2019 26 Shinohara 2019 27 Szeto 2021 28 Ting 2020 29 Tran 2017 30 Whitworth 2017 31 Akagi 2019 32 Study does not report off-label reduced dosing compared to on-label non-reduced dosing. Akao 2014 33 Amarenco 2018 34 Anouassi 2021 35 Armbruster 2014 36 Ashraf 2021 37 Blin 2019 38 Bouget 2020 39 Camm 2020 40 8
RkJQdWJsaXNoZXIy MTk4NDMw